NeOnc Technologies Holdings (NTHI) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
21 Oct, 2026Opening remarks and agenda
Meeting called to order at 10:00 A.M. Pacific; materials included the proxy statement and 2025 annual report on Form 10-K and 10-K/A.
Agenda covered confirmation of a quorum, consideration of proposals, and preliminary voting results.
Board and executive committee updates
Victoria Medvec, PhD, and Steven L. Giannotta, MD, were nominated as Class I directors for three-year terms ending at the 2029 annual meeting; the board recommended votes for both.
Shareholder proposals
Proposed an additional 1 million shares for the 2023 equity incentive plan and annual increases equal to 20% of prior year-end shares outstanding, each January 1 from 2027 through 2033.
Proposed ratification of CBIZ CPAs, P.C. as independent auditor for the fiscal year ending December 31, 2026; the board recommended approval.
Conditional adjournment proposal applied if votes or quorum were insufficient; it was not presented after quorum and sufficient votes were confirmed.
Latest events from NeOnc Technologies Holdings
- Median OS was 26.09 months and PFS6 was 48.9%, with no major toxicities reported.NTHI
Study result - Q2 2026 net loss was $14.2M; major clinical progress and liquidity concerns persist.NTHI
Q2 2026 - Direct listing on Nasdaq for a biotech with early-stage brain cancer drugs and high capital needs.NTHI
Registration filing - Direct listing of CNS-focused biotech with no commercial revenue, ongoing losses, and exclusive IP.NTHI
Registration filing - Biopharma advancing brain cancer therapies faces high clinical, financial, and regulatory risks.NTHI
Registration filing - Direct listing registers 2.1M shares for resale; early-stage pipeline, high risk, and capital needs.NTHI
Registration filing - Biotech with novel brain cancer therapies in clinical trials, high losses, and ongoing financing needs.NTHI
Registration filing - Clinical-stage biotech registers shares for resale amid ongoing losses and dilution risks.NTHI
Registration filing - Q3 net loss surged to $8.6M as clinical progress and new funding offset high expenses.NTHI
Q3 2025